Table 1.
Baseline characteristics of the NAFLD–CHB patients with a low FIB-4 index (<1.77) and NALFD-CHB patients with a high FIB-4 index (≥1.77).
| Variables | Before Propensity Score Matching | After Propensity Score Matching * | |||||
|---|---|---|---|---|---|---|---|
| Total Population (n = 237) | Low FIB-4 Index | High FIB-4 Index | p Value | Low FIB-4 Index | High FIB-4 Index | p Value | |
| (n = 147) | (n = 90) | (n = 90) | (n = 90) | ||||
| Male (vs. female) | 214 (90.3%) | 137 (93.2%) | 77 (85.6%) | 0.09 | 83 (92.2%) | 77 (85.6%) | 0.24 |
| Diabetes mellitus (yes vs. no) | 55 (23.2%) | 36 (24.5%) | 19 (21.1%) | 0.66 | 27 (30.0%) | 19 (21.1%) | 0.13 |
| Hypertension (yes vs. no) | 52(21.9%) | 28 (19.0%) | 24 (26.7%) | 0.22 | 23 (25.6%) | 24 (26.7%) | 1.00 |
| USG-LC (yes vs. no) | 37 (15.6%) | 18 (12.2%) | 19 (21.1%) | 0.1 | 16 (17.8%) | 19 (21.1%) | 0.85 |
| Body mass index (kg/m2) | 25.0 (25.0–26.8) | 25.0 (25.0–26.6) | 25.0 (25.0–27.2) | 0.56 | 25.0 (24.7–26.3) | 25.0 (25.0–27.2) | 0.37 |
| Antiviral treatment at baseline (yes vs. no) | 84 (35.4%) | 42 (28.6%) | 42 (46.7%) | 0.007 | 33 (36.7%) | 42 (46.7%) | 0.23 |
| Antiviral treatment after baseline (yes vs. no) | 132 (55.7%) | 74 (50.3%) | 58 (64.4%) | 0.047 | 51 (56.7%) | 58 (64.4%) | 0.29 |
| Aspirin use (yes vs. no) | 42 (17.7%) | 25 (32.9%) | 17 (18.9%) | 0.85 | 20 (22.2%) | 17 (18.9%) | 0.71 |
| Statin use (yes vs. no) | 49 (20.7%) | 32 (21.8%) | 17 (18.9%)) | 0.71 | 20 (22.2%) | 17 (18.9%)) | 0.47 |
| HBeAg positivity (yes vs. no) | 121 (51.1%) | 74 (50.3%) | 47 (52.2%) | 0.88 | 45 (50.0%) | 47 (52.2%) | 1 |
| HBV DNA > 2000 IU/mL (yes vs. no) | 96 (40.5%) | 61 (41.5%) | 140 (22.2%) | <0.001 | 38 (42.2%) | 35 (38.9%) | 0.65 |
| Total bilirubin (IU/L) | 0.8 (0.6–1.0) | 0.8 (0.6–1.0) | 0.8 (0.6–1.1) | 0.26 | 0.8 (0.6–1.1) | 0.8 (0.6–1.1) | 0.23 |
| Cholesterol (mg/dL) | 171.0 (151.0–194.5) | 172.0 (150.0–194.5) | 168.0 (151.0–193.0) | 0.77 | 168.0 (150.0–193.0) | 168.0 (151.0–193.0) | 0.82 |
| FIB-4 index | 1.6 (1.2–2.0) | 1.3 (1.1–1.5) | 2.2 (1.9–2.6) | <0.001 | 1.4 (1.2–1.6) | 2.2 (1.9–2.6) | <0.001 |
| Age (years) | 46.0 (39.0–52.0) | 43.0 (36.5–49.0) | 51.5 (47.0–55.0) | <0.001 | 46.5 (42.0–52.0) | 51.5 (47.0–55.0) | <0.001 |
| AST (IU/L) | 30.0 (23.0–46.0) | 25.0 (20.5–31.0) | 49.0 (36.0–67.0) | <0.001 | 24.0 (20.0–30.0) | 49.0 (36.0–67.0) | <0.001 |
| ALT (IU/L) | 41.0 (28.0–70.0) | 35.0 (26.0–51.0) | 63.5 (35.0–94.0) | <0.001 | 34.5 (25.0–48.0) | 63.5 (35.0–94.0) | <0.001 |
| Platelet (109/L) | 182.0 (150.0–220.0) | 197.0 (161.5–231.5) | 156.5 (121.0–197.0) | <0.001 | 193.0 (155.0–224.0) | 156.5 (121.0–197.0) | 0.001 |
NOTE. Data are expressed as n (%) or median (interquartile range). USG-LC, ultrasonographic liver cirrhosis; HBV, hepatitis B virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase. * Adjusted for sex, age, diabetes mellitus, ultrasonographic liver cirrhosis, BMI, history of drug use (i.e., antiviral agents at baseline, antiviral agents after baseline, aspirin, and statin), and HBV DNA levels.